MARKET

RDHL

RDHL

Redhill Biopharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

10.12
+0.33
+3.37%
Opening 12:59 02/24 EST
OPEN
9.95
PREV CLOSE
9.79
HIGH
10.38
LOW
9.94
VOLUME
295.53K
TURNOVER
--
52 WEEK HIGH
11.52
52 WEEK LOW
3.262
MARKET CAP
420.86M
P/E (TTM)
-5.6790
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22)
Benzinga · 1d ago
RedHill Biopharma Announces Planned Expansion Of Opaganib Global Phase 2/3 COVID-19 Study To The US
TEL AVIV, Israel and RALEIGH, NC, Feb. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company,
Benzinga · 1d ago
Redhill Biopharma to Expand Study of COVID Drug Candidate Opaganib to the US
MT Newswires · 1d ago
IBS Treatment Market Share,Size 2021 – Global Trends, Market Demand, Industry Analysis, Growth, Opportunities and Forecast 2023
Feb 22, 2021 (The Expresswire) -- Global IBS Treatment Market Research Report presents competitive environment such as key competitors, key trends,...
The Express Wire · 2d ago
Choroidal Neovascularization Drug Market Industry Growth,Forecast, Analysis,Manufacturers, Regions, Types and Applications 2020-2027 By Ameco Research
pune, India, Sun, 21 Feb 2021 23:48:52 / Comserve Inc. / -- Choroidal Neovascularization Drug market is segmented by Type, and by Application. Players,...
Comserve · 2d ago
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
Zacks.com · 4d ago
RedHill (RDHL) Doses First Patient in Phase II/III COVID-19 Study
Zacks.com · 5d ago
RedHill Biopharma, Cosmo Pharma In Manufacturing Pact for Movantik, RHB-204
Benzinga · 6d ago
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of RDHL. Analyze the recent business situations of Redhill Biopharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average RDHL stock price target is 22.00 with a high estimate of 27.00 and a low estimate of 12.00.
EPS
Institutional Holdings
Institutions: 86
Institutional Holdings: 11.97M
% Owned: 28.77%
Shares Outstanding: 41.59M
TypeInstitutionsShares
Increased
22
284.24K
New
22
379.09K
Decreased
13
248.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.50%
Pharmaceuticals & Medical Research
+1.39%
Key Executives
Chairman/Chief Executive Officer/Director
Dror Ben-Asher
Chief Financial Officer
Micha Ben Chorin
Chief Operating Officer
Gilead Raday
Senior Vice President
Reza Fathi
Senior Vice President
Adi Frish
Chief Scientific Officer
June Almenoff
Other/Director
Rick Scruggs
Other
Guy Goldberg
Director
Giuseppe Cipriano
Director
Nicolas Weinstein
Independent Director
Shmuel Cabilly
Independent Director
Alla Felder
Independent Director
Kenneth Reed
Independent Director
Eric Swenden
Independent Director
Ofer Tsimchi
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About RDHL
RedHill Biopharma Ltd. is an Israel-based specialty biopharmaceutical company, primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal and infectious diseases. The Company develops the gastrointestinal drugs such as: Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori, Aemcolo for the treatment of travelers’ diarrhea in adults . It's key clinical late-stage development programs include drugs such as: RHB-204, opaganib (Yeliva), RHB-102, RHB-104, RHB-107 and RHB-106. The activity of the Company is divided into two segments: Commercial Operations, and Research & Development. The Commercial Operations segment covers all areas relating to commercial sales and operating expenses directly related to that activity. The Research and Development segment includes all activities related to the research and development of therapeutic candidate.

Webull offers kinds of RedHill Biopharma Ltd (ADR) stock information, including NASDAQ:RDHL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RDHL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RDHL stock methods without spending real money on the virtual paper trading platform.